Skip to content

Guidelines

TL;DR — Retinoblastoma guidance is distributed across ocular-oncology reviews, national consensus documents, cancer-predisposition workshops and survivorship recommendations rather than one universally controlling guideline. Agreement is strongest on urgent specialist diagnosis, avoidance of routine intraocular biopsy, germline testing, stage-adapted multidisciplinary care and prioritising life over eye salvage. Divergence concerns classification, screening frequency, choice of chemotherapy route, high-risk pathology thresholds and serial MRI for trilateral disease. Recommendation provenance, year and population must therefore accompany any synthesis.

Decision-relevant evidence

  • The Indian Council of Medical Research published a coordinated 2024 three-document consensus set covering epidemiology/diagnosis/genetics, intraocular management and extraocular management; the diagnostic document frames the Indian burden as roughly 1,500 of the ~8,000 annual global cases and notes that survival exceeds 90% in high-income settings, so the recommendations are written for a resource context, not a universal one (Singh 2024, PMID 38492167; Meel 2024, PMID 38609685; Madan 2024, PMID 38639859).

  • Adult heritable-survivor consensus searched three databases, screened 139 articles and abstracted 37; risk evidence was substantial but no evidence supporting routine testing of asymptomatic survivors was identified, and only skin examination for melanoma and prompt evaluation of head-and-neck signs were judged prudent (Tonorezos 2020, PMID 32422154).

  • The AACR childhood-predisposition lineage changed its own numbers between documents: the 2017 statement described approximately 40% of retinoblastomas as hereditary with an approximately 20% risk of second primary cancers and stated that no clear consensus screening protocol existed, while the 2025 update puts hereditary disease at about 45% and revisits testing strategy, intraocular surveillance and subsequent-neoplasm surveillance (Kamihara 2017, PMID 28674118; Kamihara 2025, PMID 39998650). Citing "the AACR recommendation" without the year is therefore ambiguous.

  • There is no agreed definition of the pathology that triggers adjuvant chemotherapy. In a 2020–2021 survey answered by 27 of 52 invited specialists from 24 practices in 16 countries, only postlaminar optic-nerve infiltration, optic-nerve transection involvement and extrascleral infiltration were called high-risk by all 27 (100%). Agreement then fell away: massive (≥3 mm) choroidal invasion 93%, microscopic scleral infiltration 85%, ciliary-body infiltration 74%, trabecular-meshwork invasion 67%, iris infiltration 63%, anterior-chamber seeds 52%, laminar optic-nerve infiltration 48%, minor (<3 mm) choroidal invasion 19% and prelaminar optic-nerve infiltration 7% (Kaliki 2022, PMID 34762098).

  • Classification schemes are not interchangeable, and the disagreement is measurable rather than rhetorical. Across 1,362 enucleated patients from 16 centres in 11 countries, 751 (55.1%) had at least one high-risk feature; the positive predictive value of a group D eye for high-risk pathology was 42.0% (ICRB Philadelphia), 35.1% (ICRB Los Angeles) and 43.2% (COG), while group E gave 58.5%, 59.0% and 59.5%. Inter-scheme agreement was 0.8–0.9, and the AJCC cT categories stratified more finely, rising from above 55% at cT3a to 72.3% at cT3e (Kurian 2025, PMID 39922380).

  • Where the group-E boundary is drawn changes which eyes enter a series. Reclassifying 332 advanced eyes from IIRC to ICRB criteria upstaged 57 of 150 group D eyes (17%) to group E, and those upstaged eyes were enucleated primarily far more often (30% versus 11%, P = 0.003). Twelve-month Kaplan-Meier ocular survival was 79%, 59%, 49% and 1% for ICRB D, E1, E2 and E3 (Singh 2024, PMID 38830602). Two series reporting "group E salvage" under different criteria are therefore not comparable.

  • Trilateral screening guidance rests on two incompatible quantitative models. A 2020 meta-analysis of 138 pineal trilateral cases estimated that six-monthly MRI from diagnosis of heritable disease to 36 months of age would require at least 311 scans to detect one asymptomatic pineal tumour and 776 to save one life, with a lead time of roughly one year (de Jong 2020, PMID 32061409); a 2022 update modelled that timed additional scans could raise asymptomatic detection to 53–92% (de Jong 2022, PMID 33939299); and a 2024 prospective cohort found that following all cystic glands required 494 follow-up scans per pineal tumour versus 22 when restricted to suspicious glands (de Bloeme 2024, PMID 38992673). No document reconciles them.

  • Some survivorship domains still have no formal guideline. A 2016 review of orbital sarcomas in retinoblastoma survivors stated that no screening or treatment guidelines existed and proposed one (Baker 2016, PMID 27213925). Re-run on 2026-09-01, a PubMed query for retinoblastoma survivor sarcoma screening or surveillance restricted to the guideline, practice-guideline and consensus-development publication types returned 0 records, and the unrestricted query returned only the two consensus documents already catalogued here plus that 2016 proposal (PMIDs: 39998650, 32422154, 27213925). Sarcoma surveillance in this population is therefore governed by consensus opinion, not by an indexed society guideline, as of that date.

  • Outcome definitions are not standardised either. A scoping review of patient-reported outcome measures found 143 instruments used in retinoblastoma and adjacent fields, of which exactly one was retinoblastoma-specific (Janic 2020, PMID 32770435). Guidance that specifies treatment but not the instrument of outcome cannot be audited across centres.

  • Regional evidence needed for guideline adaptation is uneven: a systematic review of nine Latin American studies covering 1,560 patients found median time to diagnosis of 3–5 months and median age at diagnosis 16.5–22.2 months, with methodological heterogeneity that the authors argue prevents pooling (Mattosinho 2019, PMID 31014139).

  • Income stratum and access are effect modifiers rather than background: essential treatment was nominally available almost everywhere in the 2017 global cohort, yet three-year survival ranged from 99.5% to 57.3% (Global Retinoblastoma Study Group 2022, PMID 35839812). A recommendation set validated in high-income practice does not transfer on the strength of drug availability alone.

Clinical and research frame

Domain Operational meaning Evidence boundary
Diagnosis Urgent ophthalmic-oncology assessment Broad agreement
Biopsy Avoid routine transocular biopsy Safety-critical agreement
Genetics Offer comprehensive RB1 evaluation Access and assay depth vary
Eye salvage Stage/eye-specific multimodality Route differs by center/resources
Trilateral screening Baseline MRI Serial schedule disputed
Adult surveillance Skin/symptom attention Routine imaging benefit absent

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
38609685 2024 Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Meel 2024, PMID 38609685)
38639859 2024 Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Madan 2024, PMID 38639859)
32422154 2020 Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Topic-resolved source (Tonorezos 2020, PMID 32422154)
39998650 2025 Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children. Topic-resolved source (Kamihara 2025, PMID 39998650)
29915461 2018 Classification and staging of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29915461)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
28674118 2017 Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Topic-resolved source (Kamihara 2017, PMID 28674118)
39079981 2024 A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Topic-resolved source (Ryl 2024, PMID 39079981)
25473349 2014 Retinoblastoma: An overview. Topic-resolved source (Pandey 2014, PMID 25473349)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
37344582 2023 Automatic retinoblastoma screening and surveillance using deep learning. Topic-resolved source (Zhang 2023, PMID 37344582)
37497122 2023 Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies. Topic-resolved source (Feng 2023, PMID 37497122)
8271852 1994 Current management of retinoblastoma. Topic-resolved source (Shields 1994, PMID 8271852)
27213925 2016 Orbital sarcomas in retinoblastoma patients: recommendations for screening and treatment guidelines. Topic-resolved source (Baker 2016, PMID 27213925)
10651386 1999 Chemotherapy for retinoblastoma: a current topic. Topic-resolved source (Finger 1999, PMID 10651386)
37057832 2023 How we approach conservative treatment of retinoblastoma in South America in the era of local ocular treatments: A consensus of the Grupo America Latina de Oncologia Pediatrica (GALOP). Topic-resolved source (Garin 2023, PMID 37057832)
32061409 2020 Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Topic-resolved source (de 2020, PMID 32061409)
34762098 2022 Defining High-risk Retinoblastoma: A Multicenter Global Survey. Topic-resolved source (Kaliki 2022, PMID 34762098)
32770435 2020 Patient-reported outcome measures for retinoblastoma: a scoping review. Topic-resolved source (Janic 2020, PMID 32770435)
31014139 2019 Time to diagnosis of retinoblastoma in Latin America: A systematic review. Topic-resolved source (Mattosinho 2019, PMID 31014139)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
34987197 2023 Retinoblastoma and vision. Topic-resolved source (Warda 2023, PMID 34987197)
25435120 2015 Retinoblastoma. Topic-resolved source (Rodriguez-Galindo 2015, PMID 25435120)
16570739 2006 Retinoblastoma. Topic-resolved source (Melamud 2006, PMID 16570739)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
28558178 2017 Retinoblastoma: Update on Current Management. Topic-resolved source (Cassoux 2017, PMID 28558178)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
27609158 2016 Adult onset retinoblastoma. Topic-resolved source (Sengupta 2016, PMID 27609158)
2059954 1991 Retinoblastoma. Topic-resolved source (Servodidio 1991, PMID 2059954)
39922380 2025 High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Added by audit 2026-09-01 (Kurian 2025, PMID 39922380)
38830602 2024 Evolving criteria for group E retinoblastoma: impact on outcomes. Added by audit 2026-09-01 (Singh 2024, PMID 38830602)
33939299 2022 Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis. Added by audit 2026-09-01 (de Jong 2022, PMID 33939299)
38992673 2024 Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. Added by audit 2026-09-01 (de Bloeme 2024, PMID 38992673)

Source chronology

Era marker PMID What the record contributes
1991 2059954 Retinoblastoma. (Servodidio 1991, PMID 2059954)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
1994 8271852 Current management of retinoblastoma. (Shields 1994, PMID 8271852)
1999 10651386 Chemotherapy for retinoblastoma: a current topic. (Finger 1999, PMID 10651386)
2006 16570739 Retinoblastoma. (Melamud 2006, PMID 16570739)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2014 25473349 Retinoblastoma: An overview. (Pandey 2014, PMID 25473349)
2015 25435120 Retinoblastoma. (Rodriguez-Galindo 2015, PMID 25435120)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 27213925 Orbital sarcomas in retinoblastoma patients: recommendations for screening and treatment guidelines. (Baker 2016, PMID 27213925)
2016 27609158 Adult onset retinoblastoma. (Sengupta 2016, PMID 27609158)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Can guideline recommendations be harmonised by resource tier? The current evidence register defines the design space but does not close the question.

  • Which disagreements reflect evidence versus infrastructure? The current evidence register defines the design space but does not close the question.

  • How quickly will randomized IAC and adjuvant-cycle evidence change guidance? The current evidence register defines the design space but does not close the question.

References

  1. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  2. Meel R, et al. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1166-1176. PMID 38609685
  3. Madan R, et al. Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1157-1165. PMID 38639859
  4. Tonorezos ES, et al. Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology. 2020;127:1549-1557. PMID 32422154
  5. Kamihara J, et al. Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025;31:1573-1579. PMID 39998650
  6. Fabian ID, et al. Classification and staging of retinoblastoma. Community eye health. 2018;31:11-13. PMID 29915461
  7. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  8. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  9. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  10. Kamihara J, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23:e98-e106. PMID 28674118
  11. Ryl T, et al. A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology. 2024;7:919. PMID 39079981
  12. Pandey AN. Retinoblastoma: An overview. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2014;28:310-5. PMID 25473349
  13. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  14. Zhang R, et al. Automatic retinoblastoma screening and surveillance using deep learning. British journal of cancer. 2023;129:466-474. PMID 37344582
  15. Feng H, et al. Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies. International journal of public health. 2023;68:1605284. PMID 37497122
  16. Shields JA, et al. Current management of retinoblastoma. Mayo Clinic proceedings. 1994;69:50-6. PMID 8271852
  17. Baker MS, et al. Orbital sarcomas in retinoblastoma patients: recommendations for screening and treatment guidelines. Current opinion in ophthalmology. 2016;27:443-8. PMID 27213925
  18. Finger PT, et al. Chemotherapy for retinoblastoma: a current topic. Drugs. 1999;58:983-96. PMID 10651386
  19. Garin JPL, et al. How we approach conservative treatment of retinoblastoma in South America in the era of local ocular treatments: A consensus of the Grupo America Latina de Oncologia Pediatrica (GALOP). Pediatric blood & cancer. 2023;70:e30352. PMID 37057832
  20. de Jong MC, et al. Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Ophthalmology. 2020;127:601-607. PMID 32061409
  21. Kaliki S, et al. Defining High-risk Retinoblastoma: A Multicenter Global Survey. JAMA ophthalmology. 2022;140:30-36. PMID 34762098
  22. Janic A, et al. Patient-reported outcome measures for retinoblastoma: a scoping review. Journal of patient-reported outcomes. 2020;4:66. PMID 32770435
  23. Mattosinho CCS, et al. Time to diagnosis of retinoblastoma in Latin America: A systematic review. Pediatric hematology and oncology. 2019;36:55-72. PMID 31014139
  24. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  25. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  26. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  27. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  28. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  29. Warda O, et al. Retinoblastoma and vision. Eye (London, England). 2023;37:797-808. PMID 34987197
  30. Rodriguez-Galindo C, et al. Retinoblastoma. Pediatric clinics of North America. 2015;62:201-23. PMID 25435120
  31. Melamud A, et al. Retinoblastoma. American family physician. 2006;73:1039-44. PMID 16570739
  32. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  33. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  34. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  35. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  36. Cassoux N, et al. Retinoblastoma: Update on Current Management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2017;6:290-295. PMID 28558178
  37. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  38. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  39. Sengupta S, et al. Adult onset retinoblastoma. Indian journal of ophthalmology. 2016;64:485-91. PMID 27609158
  40. Servodidio CA, et al. Retinoblastoma. Cancer nursing. 1991;14:117-23. PMID 2059954
  41. Kurian DE, et al. High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Ophthalmology. Retina. 2025;9:787-797. PMID 39922380
  42. Singh A, et al. Evolving criteria for group E retinoblastoma: impact on outcomes. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2024;59:e534-e541. PMID 38830602
  43. de Jong MC, et al. Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis. Acta ophthalmologica. 2022;100:e47-e52. PMID 33939299
  44. de Bloeme CM, et al. Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. American journal of ophthalmology. 2024;268:199-211. PMID 38992673